Hannelore V Heemers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1982191/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex. Endocrine Reviews, 2007, 28, 778-808.	8.9	615
2	Androgen Signaling in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a030452.	2.9	278
3	Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. European Urology, 2017, 71, 183-192.	0.9	171
4	Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene, 2000, 19, 5173-5181.	2.6	161
5	Androgens Stimulate Lipogenic Gene Expression in Prostate Cancer Cells by Activation of the Sterol Regulatory Element-Binding Protein Cleavage Activating Protein/Sterol Regulatory Element-Binding Protein Pathway. Molecular Endocrinology, 2001, 15, 1817-1828.	3.7	140
6	Androgen Activation of the Sterol Regulatory Element-Binding Protein Pathway: Current Insights. Molecular Endocrinology, 2006, 20, 2265-2277.	3.7	110
7	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	0.9	105
8	Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells. Cancer Research, 2007, 67, 3422-3430.	0.4	101
9	Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Molecular and Cellular Endocrinology, 2003, 205, 21-31.	1.6	65
10	Androgen Modulation of Coregulator Expression in Prostate Cancer Cells. Molecular Endocrinology, 2009, 23, 572-583.	3.7	64
11	Lipid degradation promotes prostate cancer cell survival. Oncotarget, 2017, 8, 38264-38275.	0.8	64
12	Androgen Induction of the Androgen Receptor Coactivator Four and a Half LIM Domain Protein-2: Evidence for a Role for Serum Response Factor in Prostate Cancer. Cancer Research, 2007, 67, 10592-10599.	0.4	61
13	Identification of an Androgen Response Element in Intron 8 of the Sterol Regulatory Element-binding Protein Cleavage-activating Protein Gene Allowing Direct Regulation by the Androgen Receptor. Journal of Biological Chemistry, 2004, 279, 30880-30887.	1.6	58
14	RhoA as a Mediator of Clinically Relevant Androgen Action in Prostate Cancer Cells. Molecular Endocrinology, 2012, 26, 716-735.	3.7	51
15	A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. ELife, 2017, 6, .	2.8	49
16	Identification of a Clinically Relevant Androgen-Dependent Gene Signature in Prostate Cancer. Cancer Research, 2011, 71, 1978-1988.	0.4	38
17	Unraveling the Complexities of Androgen Receptor Signaling in Prostate Cancer Cells. Cancer Cell, 2009, 15, 245-247.	7.7	32
18	Androgen receptor co-regulation in prostate cancer. Asian Journal of Urology, 2020, 7, 219-232.	0.5	28

HANNELORE V HEEMERS

#	Article	IF	CITATIONS
19	The Role of the Transcriptional Coactivator p300 in Prostate Cancer Progression. Advances in Experimental Medicine and Biology, 2008, 617, 535-540.	0.8	28
20	Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells. Prostate, 2010, 70, 959-970.	1.2	22
21	Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action. Database: the Journal of Biological Databases and Curation, 2016, 2016, .	1.4	20
22	Androgen Receptor Coregulatory Proteins as Potential Therapeutic Targets in the Treatment of Prostate Cancer. Current Cancer Therapy Reviews, 2005, 1, 175-186.	0.2	18
23	Targeting Androgen Receptor Action for Prostate Cancer Treatment: Does the Post-Receptor Level Provide Novel Opportunities?. International Journal of Biological Sciences, 2014, 10, 576-587.	2.6	16
24	Novel insights in cell cycle dysregulation during prostate cancer progression. Endocrine-Related Cancer, 2021, 28, R141-R155.	1.6	16
25	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene, 2019, 38, 4496-4511.	2.6	8
26	Diversity in Androgen Receptor Action Among Treatment-naÃ⁻ve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. European Urology Open Science, 2020, 22, 34-44.	0.2	7
27	AR-dependent phosphorylation and phospho-proteome targets in prostate cancer. Endocrine-Related Cancer, 2020, 27, R193-R210.	1.6	7
28	Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic Intervention. Cells, 2022, 11, 936.	1.8	6
29	Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer. Cancers, 2021, 13, 3947.	1.7	5
30	GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models. Clinical Cancer Research, 2016, , clincanres.0137.2016.	3.2	3
31	Re: Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. European Urology, 2014, 66, 597.	0.9	2
32	Treatment-induced Treatment Sensitization in Metastatic Castration-resistant Prostate Cancer. European Urology, 2021, 79, 734-735.	0.9	2
33	ldentification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression. Current Drug Targets, 2013, 14, 481-489.	1.0	2
34	Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer. , 2010, , 41-51.		2
35	Genomic alterations impact cell cycle-related genes during prostate cancer progression. Endocrine-Related Cancer, 2021, 28, L5-L10.	1.6	1
36	Functional Studies on Steroid Receptors. Methods in Molecular Biology, 2018, 1786, 117-130.	0.4	0